Skip to main content
Clinical Trials/ISRCTN14373079
ISRCTN14373079
Completed
Phase 4

A study to survey the oral health status of Canadian seniors and to prevent poor oral health in Canadian seniors

CHX Technologies Inc0 sites151 target enrollmentAugust 18, 2023

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Decrease in chronic oral inflammation in community living (independent and assisted living) older adults and older adults living in long-term care.
Sponsor
CHX Technologies Inc
Enrollment
151
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 18, 2023
End Date
September 30, 2023
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
CHX Technologies Inc

Eligibility Criteria

Inclusion Criteria

  • 1\. Older adults (65 years of age and over at screening)
  • 2\. Residents of the Greater Ottawa community and Bruyère independent living, assisted living and longterm care
  • 1\. Matches the criteria of Phase A
  • 2\. Clears the dental screening performed in Phase A:
  • 2\.1\. Bleeding on probing at \= 12 sites at Screening
  • 2\.2\. Minimum of 15 natural teeth
  • 2\.3\. Willing and able to provide informed consent
  • 2\.4\. Able to complete the study as judged by the investigators
  • 2\.5\. Fully vaccinated against COVID 19

Exclusion Criteria

  • 1\. Not 65 years of age or over
  • 2\. No bleeding on probing at 12 or more sites at Screening
  • 3\. Not having 15 natural teeth or more
  • 4\. Active caries which, in the judgement of the investigators, could require major surgical restoration and referral to a dentist. Those that can be readily managed by the examining hygienist (for example, small caries only requiring a temporary filling or silver diamine fluoride) will still be included in Part B.
  • 5\. Severe periodontal disease which, in the judgement of the investigators, could require surgery or a level of periodontal scaling such that participation in the study will be delayed
  • 6\. Undergoing periodontal care by a dentist or hygienist which in the judgement of the investigators could confound the study results.
  • 7\. Known allergies to the ingredients of the study medications (chlorhexidine, Sumatra benzoin, ethanol and polymethylmethacrylate)
  • 8\. Taking anti\-inflammatory medication (excluding baby aspirin, prednisone or NSAIDS) or medications for periodontal conditions (e.g. Periostat, chlorhexidine rinse, PerioChip or Arestin).
  • 9\. At Screening, taking antibiotics for oral abscesses, oral pain or taking antibiotics for more than 14 days
  • 10\. Uncontrolled epilepsy

Outcomes

Primary Outcomes

Not specified

Similar Trials